

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5716932

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
OPTINOSE AS	09/12/2019

RECEIVING PARTY DATA

Name:	BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Street Address:	C/O BEAUFORT HOUSE, 51 NEW NORTH ROAD
City:	EXETER
State/Country:	UNITED KINGDOM
Postal Code:	EX4 4EP

PROPERTY NUMBERS Total: 87

Property Type	Number
Patent Number:	D530815
Patent Number:	D725769
Patent Number:	D723156
Patent Number:	D761951
Patent Number:	D773644
Patent Number:	D759805
Patent Number:	D809128
Patent Number:	6715485
Patent Number:	8327844
Patent Number:	9072857
Patent Number:	9119932
Patent Number:	8555877
Patent Number:	8555878
Patent Number:	7740014
Patent Number:	8522778
Patent Number:	7975690
Patent Number:	9205208
Patent Number:	8596278
Patent Number:	9468727
Patent Number:	7347201

PATENT

Property Type	Number
Patent Number:	8511303
Patent Number:	7543581
Patent Number:	7841337
Patent Number:	8146589
Patent Number:	7481218
Patent Number:	8047202
Patent Number:	9132249
Patent Number:	9522243
Patent Number:	7377901
Patent Number:	7854227
Patent Number:	7934503
Patent Number:	9205209
Patent Number:	9566402
Patent Number:	10286164
Patent Number:	7784460
Patent Number:	9452272
Patent Number:	8800555
Patent Number:	9168341
Patent Number:	8590530
Patent Number:	9108015
Patent Number:	8899229
Patent Number:	9144652
Patent Number:	8550073
Patent Number:	10124132
Patent Number:	8171929
Patent Number:	9038630
Patent Number:	10112021
Patent Number:	8910629
Patent Number:	9272104
Patent Number:	9010325
Patent Number:	9649456
Patent Number:	8875704
Patent Number:	8978647
Patent Number:	10076615
Patent Number:	9067034
Patent Number:	10252010
Patent Number:	9949923
Patent Number:	10300229

Property Type	Number
Patent Number:	10076614
Patent Number:	10179216
Application Number:	15246691
Application Number:	14864365
Application Number:	14798221
Application Number:	12161466
Application Number:	12279285
Application Number:	14674103
Application Number:	15481975
Application Number:	13823071
Application Number:	14315132
Application Number:	14780277
Application Number:	14946389
Application Number:	14946442
Application Number:	14694300
Application Number:	15869284
Application Number:	15879009
Application Number:	15918169
Application Number:	15924536
Application Number:	15936251
Application Number:	16093174
Application Number:	16101634
Application Number:	16102898
Application Number:	16142646
Application Number:	16153876
Application Number:	16285694
Application Number:	16525716
Application Number:	62741370
Application Number:	14929489

CORRESPONDENCE DATA

Fax Number: (703)610-6200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7036106100

Email: BoxIP@hoganlovells.com

Correspondent Name: RACHEL FLEESON

Address Line 1: 8350 BROAD STREET, 17TH FLOOR

Address Line 4: TYSONS, VIRGINIA 22102

NAME OF SUBMITTER:	RACHEL S. FLEESON
SIGNATURE:	/rsf/
DATE SIGNED:	09/13/2019
Total Attachments: 7 source=OptiNose Pharmakon Pat Security Agreement#page1.tif source=OptiNose Pharmakon Pat Security Agreement#page2.tif source=OptiNose Pharmakon Pat Security Agreement#page3.tif source=OptiNose Pharmakon Pat Security Agreement#page4.tif source=OptiNose Pharmakon Pat Security Agreement#page5.tif source=OptiNose Pharmakon Pat Security Agreement#page6.tif source=OptiNose Pharmakon Pat Security Agreement#page7.tif	

NOTICE
OF
GRANT OF SECURITY INTEREST
IN
PATENTS

United States Patent and Trademark Office

Ladies and Gentlemen:

Please be advised that pursuant to the Security Agreement dated as of September 12, 2019 (as the same may be amended, modified, restated or supplemented from time to time, the "Security Agreement") by and among the Grantors party thereto (each a "Grantor" and collectively, the "Grantors") and BioPharma Credit PLC, as Collateral Agent (the "Collateral Agent") for the Purchasers and the other Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, the patents, patent licenses and patent applications set forth on Schedule 1 attached hereto to the Collateral Agent for the ratable benefit of the Purchasers and the other Secured Parties.

The undersigned Grantor and the Collateral Agent, on behalf of the Purchasers and the other Secured Parties, hereby acknowledge and agree that the security interest in and lien on the patents, patent licenses and patent applications set forth on Schedule 1 attached hereto (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any patent, patent license or patent application.

[Signature pages follow]

Very truly yours,

OPTINOSE AS,
a Norwegian private limited liability company

By: 
Name: Helena Djupesland
Title: Member of the Board of Directors

By: 
Name: Per Djupesland
Title: Member of the Board of Directors

Acknowledged and Accepted:

BIOPHARMA CREDIT PLC,
a public limited company incorporated under the laws of England and Wales

By _____
Name:
Title:

[Signature Page to Notice of Grant of Security Interest in Patents]

Very truly yours,

OPTINOSE AS,
a Norwegian private limited liability company

By: _____

Name:

Title:

Acknowledged and Accepted:

BIOPHARMA CREDIT PLC,
a public limited company incorporated under the laws of England and Wales

By:

Name: Pedro Gonzalez de Gosio

Title: CEO and Managing Member

Pharmakon Advisors, LP
Its Investment Manager

Pharmakon Management I, LLC
Its General Partner

Schedule I
Patents, Patent Licenses and Patent Applications

Owner	Patent Number	Country	Application Number	Filing Date
OptiNose AS	D530815	US	29/213530	September 17, 2004
OptiNose AS	D725769	US	29/455723	May 23, 2013
OptiNose AS	D723156	US	29/455727	May 23, 2013
OptiNose AS	D761951	US	29/455733	May 23, 2013
OptiNose AS	D773644	US	29/517303	May 23, 2013
OptiNose AS	D759805	US	29/517305	May 23, 2013
OptiNose AS	D809128	US	29/567592	May 23, 2013
OptiNose AS	6715485	US	09/700532	March 3, 2000
OptiNose AS	8327844	US	10/813326	March 3, 2000
OptiNose AS	9072857	US	11/446424	March 3, 2000
OptiNose AS	9119932	US	11/445993	March 3, 2000
OptiNose AS	8555877	US	11/445812	March 3, 2000
OptiNose AS	8555878	US	11/445994	March 3, 2000
OptiNose AS	7740014	US	10/469103	February 26, 2002
OptiNose AS	8522778	US	12/757626	February 26, 2002
OptiNose AS	7975690	US	10/480582	June 12, 2002
OptiNose AS	9205208	US	13/180492	June 12, 2002
OptiNose AS	2714072	US	14/929489	June 12, 2002
OptiNose AS	8596278	US	10/469106	February 26, 2002
OptiNose AS	9468727	US	14/094250	February 26, 2002
OptiNose AS	7347201	US	10/469114	February 26, 2002
OptiNose AS	8511303	US	11/963063	February 26, 2002
OptiNose AS	7543581	US	10/469105	February 26, 2002
OptiNose AS	7841337	US	10/489187	September 6, 2002

Owner	Patent Number	Country	Application Number	Filing Date
OptiNose AS	8146589	US	10/509552	March 28, 2003
OptiNose AS	7481218	US	10/520380	July 2, 2003
OptiNose AS	8047202	US	12/339716	July 2, 2003
OptiNose AS	9132249	US	13/785694	July 2, 2003
OptiNose AS	9522243	US	14/816247	July 2, 2003
OptiNose AS	7377901	US	10/312242	June 19, 2001
OptiNose AS	7854227	US	10/512514	April 25, 2003
OptiNose AS	7934503	US	10/520957	July 9, 2003
OptiNose AS	9205209	US	13/724560	May 20, 2004
OptiNose AS	9566402	US	14/822404	May 20, 2004
OptiNose AS	10,286,164	US	15/393353	May 20, 2004
OptiNose AS	7784460	US	10/568391	August 16, 2004
OptiNose AS	9452272	US	13/473277	August 16, 2004
OptiNose AS		US	15/246691	August 16, 2004
OptiNose AS	8800555	US	10/570034	August 31, 2004
OptiNose AS	9168341	US	14/456767	August 31, 2004
OptiNose AS		US	14/864365	August 31, 2004
OptiNose AS	8590530	US	13/471146	September 15, 2005
OptiNose AS	9108015	US	14/058647	September 15, 2005
OptiNose AS		US	14/798221	September 15, 2005
OptiNose AS	8899229	US	11/816984	February 23, 2006
OptiNose AS	9144652	US	14/491720	February 23, 2006
OptiNose AS	8550073	US	12/281894	March 6, 2007
OptiNose AS	10124132	US	15/051622	March 6, 2007

Owner	Patent Number	Country	Application Number	Filing Date
OptiNose AS	8171929	US	12/279291	February 14, 2007
OptiNose AS	9038630	US	12/516399	November 28, 2007
OptiNose AS		US	12/161466	January 19, 2006
OptiNose AS	10112021	US	14/635561	June 8, 2007
OptiNose AS		US	12/279285	February 14, 2007
OptiNose AS	8910629	US	12/375115	July 25, 2007
OptiNose AS	9272104	US	12/293972	March 23, 2007
OptiNose AS	9010325	US	12/516404	November 28, 2007
OptiNose AS		US	14/674103	November 28, 2007
OptiNose AS	9649456	US	12/594365	April 5, 2008
OptiNose AS	8875704	US	14/274271	April 5, 2008
OptiNose AS		US	15/481975	April 5, 2008
OptiNose AS	8978647	US	12/594361	April 7, 2008
OptiNose AS	10076615	US	14/618273	April 7, 2008
OptiNose AS	9067034	US	12/681150	October 3, 2008
OptiNose AS	10252010	US	14/721097	October 3, 2008
OptiNose AS		US	13/823071	September 14, 2011
OptiNose AS	9949923	US	14/005363	March 15, 2012
OptiNose AS	10300229	US	14/380827	February 25, 2013
OptiNose AS	10076614	US	14/380801	February 25, 2013
OptiNose AS	10179216	US	14/380836	February 25, 2013
OptiNose AS		US	14/315132	June 25, 2014

Owner	Patent Number	Country	Application Number	Filing Date
OptiNose AS		US	14/780277	March 26, 2014
OptiNose AS		US	14/946389	November 19, 2005
OptiNose AS		US	14/946442	November 19, 2005
OptiNose AS		US	14/694300	April 23, 2015
OptiNose AS		US	15/869,284	January 12, 2018
OptiNose AS		US	15/879,009	January 24, 2018
OptiNose AS		US	15/918,169	March 12, 2018
OptiNose AS		US	15/924,536	March 19, 2018
OptiNose AS		US	15/936,251	March 26, 2018
OptiNose AS		US	16/093,174	October 12, 2018
OptiNose AS		US	16/101,634	August 13, 2018
OptiNose AS		US	16/102,898	August 14, 2018
OptiNose AS		US	16/142,646	September 26, 2018
OptiNose AS		US	16/153,876	October 8, 2018
OptiNose AS		US	16/285,694	February 26, 2019
OptiNose AS		US	16/525,716	July 30, 2019
OptiNose AS		US	62/741,370	October 4, 2018